Results 51 to 60 of about 59,314 (277)

Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-Gi Complex Structures.

Cell, 2020
Human endocannabinoid systems modulate multiple physiological processes mainly through the activation of cannabinoid receptors CB1 and CB2. Their high sequence similarity, low agonist selectivity, and lack of activation and G protein-coupling knowledge ...
T. Hua, Xiaoting Li, Lijie Wu, Christos Iliopoulos-Tsoutsouvas, Yuxia Wang, Meng Wu, Ling Shen, Christine A. Johnston, S. Nikas, Feng Song, Xiyong Song, Shuguang Yuan, Qianqian Sun, Yiran Wu, Shan Jiang, Travis W. Grim, Othman Benchama, Edward L. Stahl, N. Zvonok, Suwen Zhao, L. Bohn, A. Makriyannis, Zhi-jie Liu   +22 more
semanticscholar   +1 more source

Indomethacin plus minocycline coadministration relieves chemotherapy and antiretroviral drug-induced neuropathic pain in a cannabinoid receptors-dependent manner

Journal of Pharmacological Sciences, 2019
Neuropathic pain sometimes occurs during chemotherapy with paclitaxel or HIV/AIDS antiretroviral therapy with nucleoside reverse transcriptase inhibitors (NRTIs).
Willias Masocha, Amal Thomas
doaj   +1 more source

The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway

Cell Death and Differentiation, 2015
The CB1 cannabinoid receptor, the main molecular target of endocannabinoids and cannabis active components, is the most abundant G protein-coupled receptor in the mammalian brain.
C. Blázquez, A. Chiarlone, L. Bellocchio, E. Resel, P. Pruunsild, D. García-Rincón, Michael Sendtner, T. Timmusk, Beat Lutz, I. Galve-Roperh, Manuel Guzmán   +10 more
semanticscholar   +1 more source

Phenotype-Based Screening of Synthetic Cannabinoids in a Dravet Syndrome Zebrafish Model. [PDF]

, 2020
Dravet syndrome is a catastrophic epilepsy of childhood, characterized by cognitive impairment, severe seizures, and increased risk for sudden unexplained death in epilepsy (SUDEP).
Anvar, Mana, Baraban, Scott C, Griffin, Aliesha, Hamling, Kyla   +3 more
core   +1 more source

Brodifacoum does not modulate human cannabinoid receptor-mediated hyperpolarization of AtT20 cells or inhibition of adenylyl cyclase in HEK 293 cells [PDF]

PeerJ, 2019
Background Synthetic cannabinoids are a commonly used class of recreational drugs that can have significant adverse effects. There have been sporadic reports of co-consumption of illicit drugs with rodenticides such as warfarin and brodifacoum (BFC) over
Shivani Sachdev, Rochelle Boyd, Natasha L. Grimsey, Marina Santiago, Mark Connor   +4 more
doaj   +2 more sources

Novel Adamantyl Cannabinoids as CB1 Receptor Probes [PDF]

Journal of Medicinal Chemistry, 2013
In previous studies, compound 1 (AM411), a 3-(1-adamantyl) analogue of the phytocannabinoid (-)-Δ(8)-tetrahydrocannabinol (Δ(8)-THC), was shown to have improved affinity and selectivity for the CB1 receptor. In this work, we further explored the role of the 1-adamantyl group at the C-3 position in a series of tricyclic cannabinoid analogues modified at
Ganesh A, Thakur, Shama, Bajaj, Carol, Paronis, Yan, Peng, Anna L, Bowman, Lawrence S, Barak, Marc G, Caron, Demon, Parrish, Jeffrey R, Deschamps, Alexandros, Makriyannis   +9 more
openaire   +2 more sources

Reduced CB1 Cannabinoid Receptor Expression in Alzheimer's Disease and Transgenic Mouse Models

AGING MEDICINE, EarlyView.
CB1 receptor (CB1R) expression was significantly reduced in the hippocampus, medial frontal gyrus, and superior temporal gyrus of Alzheimer's patients. CB1R levels negatively correlated with amyloid‐β and tau pathology. In addition, CB1R expression was also reduced in the cortex of 5xFAD mice and in the hippocampus of Tg4‐42 mice.
Nike von Borcke, Amrei Vivian Purwien, Annik Steiert, Henrike Hasecke, Yvonne Bouter   +4 more
wiley   +1 more source

Cannabis; epidemiological, neurobiological and psychopathological issues: an update [PDF]

, 2017
This document is the Accepted Manuscript version of the following article: Maria Antonietta De Luca, Gaetano Di Chiara, Cristina Cadoni, Daniele Lecca, Laura Orsolini, Duccio Papanti, John Corkery, Fabrizio Schifano, 'Cannabis; Epidemiological ...
Cadoni, Cristina, Corkery, John, De Luca, Maria Antonietta, Di Chiara, Gaetano, Lecca, Daniele, Orsolini, Laura, Papanti, Duccio, Schifano, Fabrizio   +7 more
core   +3 more sources

Feeding induced by cannabinoids is mediated independently of the melanocortin system. [PDF]

PLoS ONE, 2008
Cannabinoids, the active components of marijuana, stimulate appetite, and cannabinoid receptor-1 (CB1-R) antagonists suppress appetite and promote weight loss.
Puspha Sinnayah, Erin E Jobst, Joseph A Rathner, Angela D Caldera-Siu, Luciana Tonelli-Lemos, Aaron J Eusterbrock, Pablo J Enriori, Emmanuel N Pothos, Kevin L Grove, Michael A Cowley   +9 more
doaj   +1 more source

Cannabidiol in Anorexia Nervosa: A Double‐Blind Randomized Placebo Controlled Pilot Study to Test Safety, Pharmacokinetics, and Symptom Change

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Anorexia nervosa (AN) is a severe psychiatric disorder marked by an intense fear of gaining weight and persistent body dissatisfaction, both during periods of underweight and after weight restoration. The endocannabinoid system may offer therapeutic benefits, particularly in reducing anxiety.
Neha Sahota, David J. Grelotti, Tyler Nguyen, Walter H. Kaye, Skylar Swindle, Raymond Suhandynata, Spencer Seely, Megan E. Shott, Guido K. W. Frank   +8 more
wiley   +1 more source